Subanesthetic ketamine: an essential adjuvant for intractable cancer pain

References 

1. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage. 2003;26(3):867–875
   • Abstract
   • Full Text
   • Full-Text PDF (109 KB)
   • CrossRef
2. Colleau SM, et al.  The essential adjuvant analgesics for neuropathic pain. Cancer Pain Release. 2002;15(2):1–8
3. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 1995;62:259–274
   • Abstract
   • Full-Text PDF (1817 KB)
   • CrossRef
4. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage. 2000;20:358–373
   • Abstract
   • Full Text
   • Full-Text PDF (193 KB)
   • CrossRef
5. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003;102:1–8
   • Full Text
   • Full-Text PDF (86 KB)
   • CrossRef
6. Mao J. Opioid-induced abnormal pain sensitivity: implication in clinical opioid therapy. Pain. 2002;100:213–217
   • Full Text
   • Full-Text PDF (65 KB)
   • CrossRef
7. Mercadante S. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage. 2003;25:302–304
   • Full Text
   • Full-Text PDF (47 KB)
   • CrossRef
8. Luczak J. The use of ketamine in the palliative care setting for the treatment of terminal cancer pain. The Sixth International Conference of St. Christopher's Hospice. London, May 1991.
9. Luczak J, Dickenson AH, Kotlińska-Lemieszek A. The role of ketamine, an NMDA receptor antagonist, in the management of pain. Prog Palliat Care. 1995;3:127–134
10. Kotlińska-Lemieszek A, Luczak J, Baczyk E, et al. Subanesthetic ketamine—an essential adjuvant for intractable cancer pain. 4th Congress of EFIC, Prague September 2003, Abstract No 468.